A number of new crown oral drugs are on the market, the latest one or the earliest launched in the spring

According to Xinhua News Agency, Japanese Prime Minister Fumio Kishida said on February 7 that the government will consider conditional early approval of the anti-covid-19 oral drug developed by Shiono Yoshi Pharmaceutical Company for marketing. Kishida said at a congressional meeting on the same day that if clinical trials prove that the oral drug is safe and effective, the government will immediately approve it.

People's Daily health clients combed and summarized the drugs that have been approved for marketing, emergency use or about to be listed, and found that since November 2021, there have been continuous new crown oral drugs in front of Taiwan.

First, Merck's Molnupiravir and Pfizer's Paxlovid have been approved for marketing or emergency use; followed by the mainland's original innovative crown oral drug VV116 was also approved for marketing in Uzbekistan with excellent clinical trial data.

If approved, it will supply 1 million people to the end of March, and plans to start increasing production in April to supply 10 million people.

Japanese COVID-19 oral drug S-217622: or approved for marketing as early as spring

The anti-COVID-19 oral drug, called "S-217622," is currently in the middle stages of clinical trials. In its Phase II and III clinical trials, the carrier of COVID-19 in asymptomatic and mildly infected people taking the drug decreased by about 63% to 80% after 4 days compared with the control group taking placebo. The company said the oral drug was also effective against the mutated new coronavirus Omiljung strain.

Ken Teyo, president of Shiono Pharmaceutical Company, said, "The company will apply for an early listing of this oral drug as early as next week. Yoshinori Shiono intends to add moderately symptomatic infected people to the current Phase III trial and begin a global clinical trial at the end of February. If the oral drug is approved for marketing, Yoshinori Shiono has the ability to supply the drug to 1 million people by the end of March, and plans to significantly increase production to 10 million people in the next fiscal year starting in April. ”

Mainland china's new crown oral drug VV116: it is expected to be listed in China in the second half of the year

The new coronavirus treatment small molecule drug VV116, jointly developed by the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, the Wuhan Institute of Virology of the Chinese Academy of Sciences, the Xinjiang Institute of Physical and Chemical Technology of the Chinese Academy of Sciences, and the Central Asia Drug Research and Development Center of the Chinese Academy of Sciences, has entered the clinical trial stage in China.

CCTV News reported that preclinical pharmacodynamic studies have shown that VV116 has a significant inhibitory activity effect on the original virus strain and variant strain of the new coronavirus in vitro, such as Delta virus. Shen Jingshan, a researcher at the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, found that oral VV116 can reduce the virus titer below the detection limit through experiments on adenovirus mouse models, which can significantly improve the pathological changes of lung tissue in experimental models.

The small molecule drug VV116 is advancing domestic marketing (expected in the second half of the year). Previously, the drug was authorized for emergency use in Uzbekistan.

Two ORAL COVID-19 drugs have been authorized for use in the United States

On December 23, the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) authorized the Merck antiviral drug (Molnupiravir) for the treatment of COVID-19, and on December 22, the U.S. FDA authorized Pfizer's COVID-19 antiviral drug Paxlovid, the first antiviral Covid-19 pill in the United States to be approved to be taken at home before a patient falls ill and is hospitalized.

Both drugs reduce the risk of hospitalization and death for people diagnosed with the virus COVID-19 and at risk of developing severe cases of the disease. Recent preclinical evidence suggests that Molnupiravir has antiviral activity against Omicron. "Paxlovid" has an 89% effectiveness in preventing hospitalization and death in patients at high risk for severe illness.

In addition to the United States, the Israeli Ministry of Health issued a statement on December 26, 2021, saying that the ministry has approved the emergency use of Paxlovid, an oral drug produced by Pfizer in the United States to treat covid-19.